Matthew Martin

About Matthew Martin

Ph.D. medicinal chemist with over 25 years of experience in lead identification/optimization and expertise in structure-based drug design-Co-inventor of FT-1101, an oral, structurally distinct and potent pan-BET bromodomain inhibitor that completed Phase I trials in patients with relapsed/refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome-Co-inventor of FT-4101, an oral, structurally distinct and potent FASN inhibitor for nonalcoholic steatohepatitis (NASH)(completed Phase I)-Member of discovery teams and co-inventor of pre-clinical candidates AMG 429 (VEGFR-2 inhibitor), AMG 900 (Aurora kinase inhibitor), and FT-8225 (liver targeted FASNi for NASH)-Co-author of 20 peer reviewed articles (including 6 first author publications) and co-inventor on over 40 patents/patent applications-Chemistry team leader that managed teams of chemists and advanced small molecule inhibitor programs in oncology (kinase inhibitors, epigenetics, and nuclear hormone receptors) and inflammation from high throughput screening to lead optimization and candidate selectionSpecialties: Medicinal chemistry, structure-based drug design, organic synthesis, kinases, oncology, synthetic organic chemistry

Experience

1. Medicinal Chemistry Lead, Innovation Lab

   Astellas Pharma

   Nov 2025 — Present · Cambridge, MA, US

Education

• Worcester Polytechnic Institute

  B.S.

  1990 — 1994

• Massachusetts Institute of Technology

  Ph.D.

  1994 — 1999

Skills

• Drug Discovery
• Lead Optimization
• Drug Design
• Heterocyclic Chemistry
• Synthetic Chemistry
• Organic Chemistry
• Medicinal Chemistry
• Nmr
• Lc-Ms
• Organic Synthesis
• Structure Based Drug Design
• Lead Change
• Chemistry
• Hplc
• Gpcrs